{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T21:27:35Z","timestamp":1773437255014,"version":"3.50.1"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1097\/ico.0b013e318289ddd8","type":"journal-article","created":{"date-parts":[[2013,3,28]],"date-time":"2013-03-28T14:26:55Z","timestamp":1364480815000},"page":"998-1001","source":"Crossref","is-referenced-by-count":31,"title":["Subconjunctival Bevacizumab Injection for Ocular Surface Squamous Neoplasia"],"prefix":"10.1097","volume":"32","author":[{"given":"Amir","family":"Faramarzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sepehr","family":"Feizi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-21-20210204","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.survophthal.2003.10.008","article-title":"Tumors of the conjunctiva and cornea.","volume":"49","author":"Shields","year":"2004","journal-title":"Surv Ophthalmol"},{"key":"R2-21-20210204","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/j.ophtha.2010.03.052","article-title":". Subconjunctivalperilesional recombinant interferon 2b for ocular surface squamous neoplasia: a 10-year review.","volume":"117","author":"Karp","year":"2010","journal-title":"Ophthalmology"},{"key":"R3-21-20210204","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0161-6420(01)00577-2","article-title":"Treatment of conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b.","volume":"108","author":"Karp","year":"2001","journal-title":"Ophthalmology"},{"key":"R4-21-20210204","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1136\/bjo.84.3.268","article-title":". Treatment of conjunctival squamous cell carcinoma with topical 5-fluorouracil.","volume":"84","author":"Midena","year":"2000","journal-title":"Br J Ophthalmol"},{"key":"R5-21-20210204","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1136\/bjo.2010.186171","article-title":"Adjuvant 5-fluorouracil in the treatment of localised ocular surface squamous neoplasia.","volume":"95","author":"Rudkin","year":"2011","journal-title":"Br J Ophthalmol"},{"key":"R6-21-20210204","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/01.ico.0000148314.86557.6a","article-title":". Topical 0.002 mitomycin C for the treatment of conjunctival-corneal intraepithelial neoplasia and squamous cell carcinoma.","volume":"24","author":"Prabhasawat","year":"2005","journal-title":"Cornea"},{"key":"R7-21-20210204","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1136\/bjo.2009.168294","article-title":"Treatment of ocular surface squamous neoplasia with mitomycin C.","volume":"94","author":"Gupta","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"R8-21-20210204","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1136\/bjo.2009.160820","article-title":". Topical chemotherapy for ocular surface squamous neoplasia: current status.","volume":"94","author":"Sepulveda","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"R9-21-20210204","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.ophtha.2007.10.039","article-title":". Long-term follow-up of conjunctival and corneal intraepithelial neoplasia with topical interferon alfa-2b.","volume":"115","author":"Schechter","year":"2008","journal-title":"Ophthalmology"},{"key":"R10-21-20210204","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.ophtha.2004.01.034","article-title":"Treatment of recurrent corneal and conjunctival intraepithelial neoplasia with topical interferon alfa 2b.","volume":"111","author":"Boehm","year":"2004","journal-title":"Ophthalmology"},{"key":"R11-21-20210204","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.clinthera.2006.11.015","article-title":"Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.","volume":"28","author":"Shih","year":"2006","journal-title":"Clin Ther"},{"key":"R12-21-20210204","first-page":"3186","article-title":". Subconjunctival anti VEGF for conjunctival intraepithelial and invasive neoplasia.","volume":"3","author":"Zaki","year":"2009","journal-title":"Aust J Basic Appl Sci"},{"key":"R13-21-20210204","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/IOP.0b013e3182392f29","article-title":"Refractory squamous cell carcinoma of the conjunctiva treated with subconjunctival ranibizumab (Lucentis): a two-year study.","volume":"28","author":"Finger","year":"2012","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"R14-21-20210204","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1136\/bjo.2008.156489","article-title":"Subconjunctival ranibizumab for squamous cell carcinoma of the conjunctiva with corneal extension.","volume":"93","author":"Teng","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"R15-21-20210204","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.bcp.2007.09.029","article-title":". Antitumor effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis.","volume":"75","author":"Selvakumaran","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"R16-21-20210204","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1136\/bjo.85.2.154","article-title":"Reliability of impression cytology for the diagnosis of ocular surface squamous neoplasia employing the Biopore membrane.","volume":"85","author":"Tole","year":"2001","journal-title":"Br J Ophthalmol"},{"key":"R17-21-20210204","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/ICO.0b013e31815b9402","article-title":". Role of impression cytology in diagnosis of ocular surface neoplasia.","volume":"27","author":"Tananuvat","year":"2008","journal-title":"Cornea"},{"key":"R18-21-20210204","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1001\/archophthalmol.2009.18","article-title":". Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study.","volume":"127","author":"Dastjerdi","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"R19-21-20210204","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jtos.2012.01.005","article-title":". Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin).","volume":"10","author":"Stevenson","year":"2012","journal-title":"Ocul Surf"},{"key":"R20-21-20210204","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/ICO.0b013e318159019f","article-title":". Subconjunctival bevacizumab injection for corneal neovascularization.","volume":"27","author":"Bahar","year":"2008","journal-title":"Cornea"},{"key":"R21-21-20210204","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/ICO.0b013e31817786ad","article-title":"Subconjunctival bevacizumab for corneal neovascularization.","volume":"27","author":"Doctor","year":"2008","journal-title":"Cornea"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ICO.0b013e318289ddd8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T19:35:11Z","timestamp":1621884911000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003226-201307000-00021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0b013e318289ddd8","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}